Current hepatitis C treatments are combinations of drugs called direct-acting antivirals (DAAs). DAAs directly target the hep C virus in different ways to stop it from reproducing. They do this so well that they promise bright futures for those living with hepatitis C and treatments with short treatment times, high cure rates, and few side effects.
There are four classes of direct-acting antivirals that combine in different ways to make up the different hep C DAA treatments. For example, sofosbuvir and velpatasvir combine to make Epclusa.
|DAAs||Very Roughly What the DAAs Do||DAAs Covered by BC PharmaCare (Targeted Genotypes in brackets)|
|NS3/4A Protease Inhibitors (PIs)||NS3/4A protease inhibitors work by blocking a viral enzyme (protease) that enables the hep C virus to survive and replicate in host cells.||Glecaprevir (1-6)|
Grazoprevir (1, 4)
|Nucleoside and Nucleotide NS5B Polymerase Inhibitors||They directly target the hep C virus to stop it from making copies of itself in the liver. They attach themselves onto the genetic information, called RNA, to block the virus from multiplying.||Sofosbuvir (1-6)|
|NS5A Inhibitors||They block a virus protein, NS5A, that hep C needs to reproduce and for various stages of infection.||Pibrentasvir (1-6)|
Elbasvir (1, 4)
|Non-Nucleoside NS5B Polymerase Inhibitors||They work to stop hep C from reproducing by inserting themselves into the virus so that other pieces of the hep C virus cannot attach to it.|